Abstract: Provided herein, inter alia, are methods of detecting the presence of extrachromosomal DNA (ecDNA) in esophageal cells obtained from a subject who has esophageal cancer or who is at risk of developing esophageal cancer. Provided are methods for treating esophageal cancer, including detecting the presence of ecDNA and administering an esophageal cancer treatment.

Abstract: There are provided, inter alia, methods for treatment of cancer. The methods include means of identifying the NAD biosynthetic pathway on which depend cancer cells in a tumor, in a subject suffering from cancer. The methods further include administering to a subject in need a therapeutically effective amount of an inhibitor of the NMRK1 enzyme pathway to a tumor where the cancer cells are dependent of the NAD salvage pathway, allowing to lower the of dose FK866 administered to the subject. The methods also include administering to a subject in need a therapeutically effective amount of a bacterial inhibitor of NADSYN1 to a tumor where the cancer cells depend on the Preiss Handler pathway.

Abstract: Provided herein are, inter alia, methods and compositions to detect, monitor and treat cancer, wherein the cancer includes amplified extrachromosomal oncogenes. The methods are useful for personalized treatment and exploit differential expression of amplified extrachromosomal oncogenes in cancer cells versus healthy cells.

Abstract: Provided herein are, inter alia, methods and compositions to detect, monitor and treat cancer, wherein the cancer includes amplified extrachromosomal oncogenes. The methods are useful for personalized treatment and exploit differential expression and chromatin structure of extrachromosomal oncogenes in cancer cells.

Abstract: Provided herein are, inter alia, methods and compositions to detect, monitor and treat cancer, wherein the cancer includes amplified extrachromosomal oncogenes. The methods are useful for personalized treatment and exploit differential expression of amplified extrachromosomal oncogenes in cancer cells versus healthy cells.

Abstract: Provided herein are, inter alia, methods of treating cancer in a subject having or being at risk of developing cancer, wherein the subject has an amplified extrachromosomal oncogene. The treatment methods provided herein target cancer cells that include extrachromosomal DNA by administering a therapeutically effective amount of a DNA repair pathway inhibitor (e.g., a PARP inhibitor). The methods provided herein are furthermore useful to indicate the progressiveness of cancer, and/or to facilitate evaluation of responsiveness to therapy.

Abstract: Provided herein are, inter alia, methods and compositions to detect, monitor and treat cancer, wherein the cancer includes amplified extrachromosomal oncogenes. The methods are useful for personalized treatment and exploit differential expression of amplified extrachromosomal oncogenes in cancer cells versus healthy cells.

Abstract: The present teachings describe methods for selecting informative genetic markers including single nucleotide polymorphisms (SNPs) that may be used in the design and execution of genome wide association studies. These methods are distinguished from other methods relying on a predefined haplotype block structure and may be configured to make use of correlations that occur across neighboring haplotype blocks. The disclosed methods may further be implemented across chromosomal regions having both high and low local linkage disequilibrium. Informative genetic marker selection, as described, provides an alternative and potentially more efficient mechanism to select genetic markers such as SNPs using block-based and random approaches.